Short Communication - (2023) Volume 12, Issue 5
Received: 01-Sep-2023, Manuscript No. jmmd-23-115640;
Editor assigned: 04-Sep-2023, Pre QC No. P-115640;
Reviewed: 18-Sep-2023, QC No. Q-115640;
Revised: 23-Sep-2023, Manuscript No. R-115640;
Published:
30-Sep-2023
, DOI: 10.37421/2161-0703.2023.12.431
Citation: Patrick, Aisha. “A Detailed Explanation on the
Epidemiology, Pathogenesis, Diagnosis, Treatment and Prevention of
Human Monkeypox.” J Med Microb Diagn 12 (2023): 431.
Copyright: © 2023 Patrick A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Monkeypox is caused by the monkeypox virus (MPXV), a member of the Orthopoxvirus genus. It was first discovered in monkeys in 1958, leading to its name, but it can also infect humans. Monkeypox is endemic in Central and West African regions, primarily the Democratic Republic of Congo (DRC), Nigeria and Cameroon. However, sporadic cases and outbreaks have been reported beyond these areas. The primary mode of transmission is zoonotic, with rodents serving as natural reservoir hosts. Direct contact with infected animals or their bodily fluids can transmit the virus to humans. Human-tohuman transmission can occur through respiratory droplets, contact with skin lesions, or fomites (inanimate objects contaminated with the virus). The virus can be highly contagious, with a Reproduction Number (R0) ranging from 0.6 to 4.7. Monkeypox exhibits seasonal variation, often peaking during the dry season when people have more contact with rodents due to agricultural activities. The incidence varies widely, with some years seeing no reported cases while others experience outbreaks. Individuals at higher risk of infection include those living in endemic regions, healthcare workers and individuals with close contact with animals or infected persons. Additionally, age plays a role, with children often more susceptible to severe disease [1].
Upon entry through the respiratory tract or broken skin, MPXV initially infects mucosal surfaces and dendritic cells. It then travels to regional lymph nodes, leading to viremia and systemic spread. This phase is marked by non-specific flu-like symptoms, including fever, malaise and headache. The host's immune system plays a crucial role in controlling the infection. Both humoral (antibodies) and cellular (T cells) immune responses are involved. Individuals with previous smallpox vaccination may have some degree of cross-immunity, which can influence disease severity. Monkeypox presents in two distinct forms: a mild, self-limiting form and a severe, potentially fatal form. The severe form is more common in Africa. Symptoms progress from fever and malaise to the development of a rash, which progresses from macules to pustules. Lymphadenopathy is a characteristic feature. Severe cases can lead to complications such as pneumonia, encephalitis and sepsis. The virulence factors of MPXV are still under investigation, but it is known to encode proteins that interfere with the host's immune response, allowing the virus to evade detection and clearance. Clinical diagnosis of monkeypox can be challenging due to its similarity to other poxvirus infections, such as chickenpox and smallpox [2].
A thorough evaluation of Cidofovir and brincidofovir, antiviral medications used for other poxvirus infections, have shown some efficacy against MPXV in vitro and in animal studies. However, their clinical use in humans remains investigational. The smallpox vaccine, which provides partial cross-protection against monkeypox, has been used during outbreaks. Additionally, the development of a monkeypox-specific vaccine is underway to address this emerging threat. Strict infection control measures are crucial to preventing human-to-human transmission in healthcare settings. This includes isolating infected individuals, using Personal Protective Equipment (PPE) and practicing proper hand hygiene. Early detection and reporting of cases are essential for outbreak control. Surveillance systems must be in place to monitor and respond to monkeypox cases promptly. Public health interventions, such as community education on disease prevention, reducing contact with wildlife and vaccination campaigns, can help mitigate monkeypox transmission. Ongoing research is vital for understanding the virus, its reservoir hosts and the development of effective vaccines and antiviral therapies. In the preceding sections, we have examined the various facets of human monkeypox, including its epidemiology, pathogenesis, diagnosis, treatment and prevention. This comprehensive understanding of the disease allows us to appreciate both the complexities it presents and the strategies available to manage and mitigate its impact. In this discussion, we will delve deeper into the significance of each aspect and the challenges they pose [3].
Monkeypox as an Emerging Threat, while monkeypox has traditionally been endemic in Central and West African regions, sporadic cases and outbreaks beyond these areas have raised concerns about its potential to emerge as a global health threat. As the world becomes more interconnected through travel and trade, the virus can be transported across borders, potentially leading to outbreaks in previously unaffected regions. The observed seasonality of monkeypox, with a peak during the dry season, highlights the influence of human behavior on disease transmission. Agricultural activities during this period can bring people into closer contact with rodents, the primary reservoirs of the virus. Understanding these patterns can guide public health interventions and raise awareness among at-risk populations. The role of smallpox vaccination in providing partial cross-immunity against monkeypox underscores the importance of past vaccination efforts. However, as smallpox vaccination programs have been largely discontinued, the level of population immunity may have decreased, potentially rendering more individuals susceptible to monkeypox. The pathogenesis of monkeypox is still being elucidated, but the virus's ability to evade the host immune response is a significant factor in disease progression. Understanding the specific virulence factors and mechanisms involved is essential for the development of targeted therapies [4,5].
Human monkeypox is a complex and potentially severe disease with a broad range of clinical presentations. Its epidemiology, pathogenesis, diagnosis, treatment and prevention strategies are continually evolving as researchers and healthcare professionals work to better understand and combat this emerging infectious threat. Early detection, rigorous infection control and the development of effective vaccines and antiviral therapies are essential components of managing monkeypox outbreaks and reducing its impact on affected communities. Continued research into monkeypox's epidemiology, pathogenesis and treatment options is essential. Additionally, building diagnostic and treatment capacity in endemic regions, along with the development of a monkeypox-specific vaccine, can contribute to effective disease control. Moreover, a global perspective is needed, recognizing that monkeypox is not confined to specific geographic areas. Preparedness, early detection and rapid response are crucial components of a coordinated international effort to mitigate the spread and impact of this emerging infectious disease. By combining scientific knowledge with practical measures, we can strive to reduce the threat posed by human monkeypox and protect the health and well-being of vulnerable populations.
None.
There are no conflicts of interest by author.
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Medical Microbiology & Diagnosis received 14 citations as per Google Scholar report
